# TMDX — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-01. Informational only, not financial advice.

**Recommendation:** HOLD

**Scores (0–100):** Overall 6.5 · Fundamentals 8.5 · Technicals 4 · Growth 9 · Risk 7.5

## Summary

TMDX's fundamental strength in organ preservation technology remains compelling with robust revenue growth (30.24% Y/Y TTM) and high ROE (45.22%), but severe negative technical momentum and elevated debt levels create significant near-term risk. The stock trades at a steep discount to its 52-week high ($67.29 vs $156), yet persistent short interest (23.02%) and bearish forecast bands suggest limited upside without catalysts.

## Price targets (6-month horizon)

- Bear: $60.10
- Base: $80.00
- Bull: $95.00

## News context

Recent news highlights TMDX's strong growth profile (30% revenue growth) and strategic positioning in organ preservation technology, but also underscores risks: insider sales ($722K sale), high short interest (23.02%), and a 45% stock drop YTD. Stifel's Hold rating with $80 target provides some analyst validation, yet the stock remains significantly below its 52-week high ($156) despite positive operational metrics. The OCS platform's potential to extend organ viability is a key growth driver but faces regulatory uncertainty.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/tmdx-ai-stock-forecast-213fd4cd8160fdac9124363d385cff85
- AI-generated; model outputs can be wrong. Not financial advice.